Gou Young Koh

This inventor holds 15 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Angiogenesis Therapeutics. Top assignees: Korea Advanced Institute of Science and Technology, Aprogen Inc., Institute for Basic Science. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gou Young Koh. Retrieved from https://idiyas.com/inventor/gou-young-koh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 8)

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 2.3

ph-index = 4

Forward Citations = 25(Granted Patents)

Location History:

Pohang, KR (2006 - 2010)
Daejeon, KR (2010 - 2024)

Company Filing History:

8 out of 2,795

Korea Advanced Institute of Science and Technology

Institute for Basic Science

patents

4. 1 out of 130

Inha-Industry Partnership Institute

patents

5. 1 out of 132,108

Samsung Electronics Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

Anti-Angiopoietin-2 Antibodies

Tie2 Activation

VEGF Fusion Proteins

Eye Disease Treatment

Erectile Dysfunction Therapy

Chimeric Molecules

Angiogenesis Induction

Ischemic Disease

Glycosylated VEGF Decoy Receptor

Coiled Coil Chimeric Molecule

Wound Healing

Angiopoietin-4 Protein

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331106 - Anti-angiopoietin-2 antibodies that induce Tie2 activation (2025-06-17),

2. 12024562 - Antibody binding to Tie2 and use thereof (2024-07-02),

3. 11498962 - Anti-angiopoietin-2 antibodies that induce Tie2 activation (2022-11-15),

4. 10745472 - Composition for preventing and treating eye diseases including anti-Ang2 antibody (2020-08-18),

5. 10259860 - Fusion proteins binding to VEGF and angiopoietin (2019-04-16),

6. 9777261 - Glycosylated VEGF decoy receptor fusion protein (2017-10-03),

7. 9505841 - Use of an anti-Ang2 antibody (2016-11-29),

8. 9498516 - Composition for preventing or treating erectile dysfunction comprising angiopoietin-4 protein (2016-11-22),

9. 8927232 - Fusion protein capable of binding VEGF-A and TNF-alpha (2015-01-06),

10. 8414877 - Method for inducing angiogenesis in an infarcted heart by administering a coiled coil chimeric molecule (2013-04-09),

11. 8206698 - Method of treating a cutaneous wound using a coiled coil chimeric molecule (2012-06-26),

12. 7691366 - Chimeric CMP-Ang1 molecule (2010-04-06),

13. 7691365 - Methods of using chimeric coiled coil molecule to treat ischemic disease (2010-04-06),

14. 7309586 - Chimeric coiled coil molecules (2007-12-18),

15. 7081443 - Chimeric comp-ang1 molecule (2006-07-25),

Title: **Innovative Contributions of Inventor Gou Young Koh**

Introduction

Gou Young Koh is a distinguished inventor based in Daejeon, South Korea. With an impressive portfolio of 14 patents, he has made significant strides in the field of medical biotechnology, particularly concerning angiogenic diseases. His pioneering inventions demonstrate a commitment to advancing healthcare solutions through innovative antibody therapies.

Latest Patents

Among his latest patents, one notable invention is directed towards an antibody that binds to Tie2 and its related components. This invention addresses the need for a therapeutic composition aimed at preventing or treating angiogenic diseases. It encompasses an antibody or antigen-binding fragment, the nucleic acid encoding it, and a manufacturing method, providing a comprehensive approach to tackling complex medical conditions.

Another significant patent involves the development of anti-angiopoietin-2 (Ang2) antibodies that induce Tie2 activation. These mouse antibodies not only bind to Ang2 but also hold the dual functionality of activating the Tie2 receptor while neutralizing Ang2. The therapeutic implications of these anti-Ang2 antibodies are profound, as they possess the capability to normalize abnormal and pathological blood vessels, offering hope for various diseases associated with vascular abnormalities.

Career Highlights

Gou Young Koh has been associated with prominent institutions, including the Korea Advanced Institute of Science and Technology and Aprogen Inc. His work in these organizations has significantly contributed to the advancement of biopharmaceutical innovations, solidifying his reputation as a leading inventor in the biotechnology sector.

Collaborations

Throughout his career, Gou Young Koh has collaborated with several esteemed colleagues, including Chung-Hyun Cho and Jaeryung Kim. These collaborations have fostered an enriched environment for innovation and research, leading to the development of groundbreaking therapeutic solutions.

Conclusion

Gou Young Koh's impressive patent portfolio and his commitment to research in angiogenic diseases showcase the vital role of inventors in pushing the boundaries of medical science. His work continues to inspire future innovations, reaffirming the importance of collaborative efforts in the pursuit of transformative health solutions.

Profile summary based on public USPTO records.